Brief: Pfizer Investment to Jointly Commercialize Cancer Drugs with China Resources Pharmaceutical
Nov 26 (Reuters) - Pfizer Investment Co Ltd:
* SIGNS STRATEGIC PARTNERSHIP WITH CHINA RESOURCES
PHARMACEUTICAL
COMMERCIAL GROUP TO JOINTLY COMMERCIALIZE FOUR KEY DRUGS FOR
BREAST AND LUNG CANCER
Source text
Further company coverage: 3320.HK
(Reporting by Beijing newsroom)
((Ella.Cao@thomsonreuters.com;))
Recent news on China Resources Pharmaceutical
See all newsBrief: China Resources Pharmaceutical Group Declares Interim Dividend Of RMB0.087 Per Share
Brief: China Resources Pharmaceutical Says Tasly Pharmaceutical Posts HY Net Profit Attributable Of RMB 892.7 MLN
Brief: China Resources Pharmaceutical Group Says HY Revenue RMB 1.93 Billion For CR Jiangzhong
Brief: China Resources Pharmaceutical Group Posts HY Revenue RMB 1.64 Billion, Down 50.97% For KPC Pharmaceuticals
Brief: China Resources Pharmaceutical Says CR Boya Bio-Pharmaceutical Posts Quarterly Unaudited Revenue RMB 321.1 Million, Net Profit RMB 30.0 Million